Strides Pharma Science Limited is pleased to announce that Aditya Puri joins the Strides Group as an Advisor and also will be a Director of its associate Company, Stelis Biopharma.
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Kauliv provides reusable and disposable pen2 device options to cater to the global market demand.
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
This is the ninth Covid-19 vaccine approved in India
The company has started manufacturing the Sputnik Light vaccine
Sputnik M is a new member of the Sputnik vaccines family
The first batch will be shipped to the Gamaleya Center for the quality control
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)